Today: 7 February 2026
Subscribe
Browse Category

Pharma News News 24 September 2025 - 18 October 2025

ATAI Life Sciences Skyrockets on FDA Breakthrough and $130M Cash Infusion

ATAI Life Sciences Skyrockets on FDA Breakthrough and $130M Cash Infusion

Key Facts – October 18, 2025 Stock Soars on Breakthrough News and Funding Boost ATAI’s stock price surged in the last few days amid a flurry of good news. Shares jumped 17.7% on Friday (Oct 17) alone, finishing at $6.45marketbeat.com, after trading around the mid-$5 range earlier in the week. In fact, as of early Friday, ATAI was already up about 8% for the week on anticipation of the announcementsnasdaq.com. The strong finish came as investors digested multiple catalysts: a coveted FDA designation for a key drug, a fresh capital raise, and bullish commentary from analysts. Notably, after-hours trading on
18 October 2025
·····
Moderna’s Wild Ride: Vaccine Hopes Fuel Stock Pop Amid “One-Hit Wonder” Fears

Moderna’s Wild Ride: Vaccine Hopes Fuel Stock Pop Amid “One-Hit Wonder” Fears

Stock Rebounds on Moderna’s “Make-or-Break” Week Moderna’s stock is back in the spotlight after a turbulent week of news that sent the Nasdaq-listed shares swinging. On Wednesday, MRNA jumped over 5%, climbing to around $27.7 by market close marketbeat.com. The mini-rally came amid a flurry of developments – from upbeat trial data on a new cancer vaccine to analysts debating whether Moderna’s future is bright or bleak. Even after the pop, however, Moderna’s stock is a shadow of its former self: shares have cratered roughly 80% below last year’s levels marketbeat.com and are down one-third in 2025 alone. The once
16 October 2025
··
Praxis Precision (PRAX) Stock Skyrockets on Game-Changing Phase 3 Results – What Experts Say

Praxis Precision (PRAX) Stock Skyrockets on Game-Changing Phase 3 Results – What Experts Say

Market Outlook With the stock now trading well above $150, investors are debating how much further PRAX could rise. If ulixacaltamide wins approval, analysts believe it could capture a sizable ET market. However, success in neurology trials can be binary – failures or setbacks could send the stock sharply down. Looking ahead, Praxis expects more data by late 2025/early 2026 (e.g. vormatrigine POWER1 topline, PRAX-562 EMBOLD readoutnasdaq.comneurologylive.com). Management’s guidance (via press releases and presentations) has focused on these milestones rather than concrete revenue forecasts, which is typical for clinical-stage biotechsnasdaq.com. In the near term, analysts will scrutinize FDA feedback and
16 October 2025
·····
MIRA Pharma Stock Skyrockets 100% Overnight as New Pain Drug Outshines Morphine

MIRA Pharma Stock Skyrockets 100% Overnight as New Pain Drug Outshines Morphine

Stock Soars on Breakthrough Announcement MIRA Pharmaceuticals’ stock price skyrocketed overnight on the back of surprising good news. The relatively obscure biotech – which trades on the Nasdaq Capital Market under ticker MIRA – closed Wednesday, Oct. 15 at $1.32 per sharebenzinga.com. That modest close (up less than 1% on the day) gave little hint of what was to come. After the market shut, MIRA stunned investors with a press release detailing remarkable lab results for its lead drug candidate. The reaction was immediate: shares surged 68.94% in after-hours trading, reaching $2.23benzinga.com. And the rally didn’t stop there. By Thursday
16 October 2025
···
Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Biotech Bombshell: Omeros Stock Skyrockets on $2.1B Novo Nordisk Deal – What’s Next?

Stock Performance: Recent Surge and Volatility Omeros shares were trading around $4–$4.60 through early October, then exploded on Oct. 15. Data from the company’s IR site show OMER jumped from $4.10 (Oct 14 close) to $10.42 by Oct 15 closeinvestor.omeros.com. Intraday on Oct 15, it even hit a high around $12.10. This roughly 150% one-day surge was driven by the Novo Nordisk deal (see below). Trading volume was staggering: Benzinga reports ~89.2 million shares traded (vs. a ~1.1M daily average) during the rallybenzinga.com. By mid-October 16 pre-market, OMER was around $9–10 per share – still far above levels seen just days
16 October 2025
····
Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Deal Details: Novo Licenses Omeros’s MASP-3 Inhibitor On Oct. 15, Novo Nordisk and Seattle-based Omeros announced a definitive asset purchase and license agreement. Under the terms, Novo gains exclusive global rights to zaltenibart (OMS906) for all indications. Omeros will receive $340 million up front and near-term milestones, plus up to $2.1 billion total with development and sales milestones and tiered royalties Novonordisk. Reuters reported Novo would pay “up to $2.1 billion” for the experimental drug Reuters. The deal is structured as a licensing asset purchase, not a full acquisition, and is expected to close in Q4 2025 Marketscreener Novonordisk. Novo’s Chief Scientific
15 October 2025
······
Quoin Pharma (QNRX) Stock Skyrockets 150% on Funding Deal – What’s Next?

Quoin Pharma (QNRX) Stock Skyrockets 150% on Funding Deal – What’s Next?

(Source: Nasdaq/GlobeNewswire, Reuters, TipRanks, Finviz, company filings.) Company Overview: Rare Disease Focus and Pipeline Progress Quoin Pharmaceuticals Ltd. is a clinical-stage biotech specializing in rare dermatological diseases. Headquartered in Ashburn, VA, Quoin’s mission is to deliver the first approved therapies for conditions that currently have none. “We remain fully focused on delivering the first approved therapy for Netherton Syndrome,” said CEO Dr. Michael Myers globenewswire.com. The company’s pipeline comprises three main product candidates targeting multiple orphan indications finviz.com: Until recently, Quoin had additional assets (QRX004 for epidermolysis bullosa, and QRX007 for Netherton) but shelved those programs in mid-2025 to concentrate
11 October 2025
····
Bristol Myers Snaps Up Orbital Therapeutics in $1.5B Biotech Power Play

Bristol Myers Snaps Up Orbital Therapeutics in $1.5B Biotech Power Play

In-Depth Analysis BMS’s acquisition of Orbital Therapeutics marks a deliberate push into autoimmune disease treatment via advanced cell therapy. Orbital, founded in 2022 by leaders in RNA and immunology, has built a proprietary RNA platform combining circular and linear RNA engineering with sophisticated lipid nanoparticle (LNP) delivery Bms Fiercebiotech. Its lead program, OTX-201, is designed as an in vivo CAR‑T: instead of harvesting and engineering cells outside the body, Orbital will inject circular RNA encoding a CD19-directed CAR into the patient, so the patient’s own T cells become the “manufacturers” of CAR‑T cells in situ Bms Orbitaltx. This approach could
10 October 2025
·····
Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside

Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside

Intellia Background and Pipeline Intellia was an early pioneer of in-vivo CRISPR therapy. Based in Cambridge, MA, it was among the first to administer CRISPR-Cas9 therapies directly into patients ts2.tech. In 2021 Intellia reported the first clinical proof that in-body CRISPR editing could work – a single injection dramatically lowered the disease protein (transthyretin) in ATTR amyloidosis patients ts2.tech. Today, the company’s focus is on curative gene edits in severe diseases. Its lead programs are NTLA-2001 (nexiguran ziclumeran) for transthyretin amyloidosis (ATTR) and NTLA-2002 (lonvoguran ziclumeran) for hereditary angioedema (HAE) ts2.tech ts2.tech. Both use CRISPR delivered via lipid nanoparticles to
9 October 2025
···
Dyne Therapeutics Skyrockets on Breakthrough Data – Inside the Surge, Financials & 2026 Catalysts

Dyne Therapeutics Skyrockets on Breakthrough Data – Inside the Surge, Financials & 2026 Catalysts

Recent Stock Performance & Surge on Data Dyne Therapeutics’ stock has been on a tear following its latest clinical breakthroughs. Shares jumped 10–11% intraday on October 7, 2025, after the company reported positive one-year results from a key trial, lifting the stock to about $14.02 by mid-daymarketbeat.commarketbeat.com. This rally builds on a strong upward trend in recent months – the stock traded below $8 in spring 2025, so it has nearly doubled since then. Trading volume actually dipped on the spike (about 331,000 shares vs. a 2.6 million average), indicating the price jolt came on limited activitymarketbeat.commarketbeat.com. Still, the momentum
7 October 2025
····
Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough – Inside the Stock Surge, Pipeline & Outlook (Oct 2025)

Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough – Inside the Stock Surge, Pipeline & Outlook (Oct 2025)

Stock Performance & Financial Metrics (as of Oct 7, 2025) Spruce Biosciences’ stock chart for 2025 looks like a hockey stick – mostly flat/down all year and then vertical in October. On Monday, Oct 6, SPRB opened around $8.60 and skyrocketed to $130.40 by the close (+1,378%) after the FDA news. The 52-week high was shattered in the process (previously the stock had been languishing below $2 pre-split, equivalent to <$150 post-split). Volume surged into the tens of millions of shares, far exceeding the tiny float, as investors clamored for a piece of the action. The rally continued after hours
7 October 2025
····
Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Cidara Therapeutics (CDTX) Stock and Company Update as of September 24, 2025 Stock Performance & Technical Analysis Cidara’s stock has been on a tear in 2025, delivering triple-digit percentage gains. Year-to-date, CDTX has risen about +173% as of late September investing.com, driven by upbeat trial results and investor enthusiasm for its flu program. The stock recently surged over 20% in one day after the Phase 3 acceleration news, reaching an intraday high of approximately $87.75 on Sept. 24 marketbeat.com marketbeat.com. This is effectively a new 52-week (and all-time) high, far above its 52-week low of ~$10 marketbeat.com. By comparison, Cidara’s market capitalization now stands around $2.0–2.3 billion at these prices
24 September 2025
··
1 … 8 9 10 11

Stock Market Today

Meta stock faces an AI split: ad gains vs a $135 billion bill

Meta stock faces an AI split: ad gains vs a $135 billion bill

7 February 2026
Meta shares dropped 1.3% to $661.46 on Friday after the company projected 2026 capital spending of up to $135 billion, raising investor concerns over cash flow. Meta reported Q4 revenue of $59.89 billion, up 24% year-over-year, with ad impressions rising 18%. Analysts remain divided on whether AI-driven ad gains can offset the steep spending ramp.
IAG share price jumps toward a 52-week peak — what to watch before London reopens

IAG share price jumps toward a 52-week peak — what to watch before London reopens

7 February 2026
IAG shares rose 4.33% to 438.50 pence Friday, near their 52-week high, ahead of full-year results due later this month. The company reported 162,073,135 treasury shares and total voting rights of 4,565,128,012. Brent crude fell 2.2% Thursday to $67.93 a barrel. South Europe Ground Services logged 712,340 operations in 2025 and seeks approval to operate in Portugal.
Go toTop